Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I
| Autor: | William B. Abrams, Turini Ga, HJ Gomez, Hans R. Brunner, K. H. Jones, M Burnier, M. Porchet, D. B. Brunner, Jérôme Biollaz, Gavras H, F Ferber |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Adult
Male medicine.medical_specialty Angiotensins Angiotensin-Converting Enzyme Inhibitors Blood Pressure Peptidyl-Dipeptidase A Pharmacology law.invention law Internal medicine Renin Renin–angiotensin system medicine Humans Pharmacology (medical) Aldosterone Clinical pharmacology Angiotensin II receptor type 1 Dose-Response Relationship Drug biology Chemistry Angiotensin II Angiotensin-converting enzyme Enzyme assay Blockade Blood pressure Endocrinology biology.protein Onset of action Angiotensin I |
| Zdroj: | Clinical Pharmacology and Therapeutics. 29:665-670 |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | Three new angiotensin converting-enzyme inhibitors were given orally to 20 men in single doses ranging from 1.25 to 40 mg. Two of them induced comparable marked inhibition of both the blood pressure response to exogenous angiotensin I and plasma converting-enzyme activity. Onset of action was relatively slow, but 21 to 24 hr after drug plasma converting-enzyme activity was still clearly reduced. The third was less active. There was a close correlation between blood pressure response on administration of angiotensin I and plasma converting-enzyme activity. There were no adverse effects. These new drugs are interesting because of their long duration of action. The measurement of plasma converting-enzyme activity seems useful for monitoring efficacy of converting-enzyme blockade and compliance to therapy. Clinical Pharmacology and Therapeutics (1981) 29, 665–670; doi:10.1038/clpt.1981.92 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text